Trial: 201910168

A phase I study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in multiple myeloma patients following autologous stem cell transplant in the front-line setting.

Phase

I/II (Cancer Control)

Principal Investigator

Vij, Ravi

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov